Free public records show MediLink Therapeutics (Suzhou) Co., Ltd. in 5 of the markets we cover. It is not a key player in our research.
[1] ClinicalTrials.gov, Studies led by MediLink Therapeutics (Suzhou) Co., Ltd. or a part of it that are recruiting, about to start or running. Retrieved 13 Nov 2026.
From public registers, not from Acuitas research, with a citation under every number. Each card opens the full list at its source.
23 active studies led by MediLink Therapeutics (Suzhou) Co., Ltd., of 23 in all
Source: ClinicalTrials.gov, Studies with MediLink Therapeutics (Suzhou) Co., Ltd. (or a part of it) as lead sponsor; active = recruiting, about to start or running. Retrieved 13 Nov 2026.
1 510(k) clearances and PMA approvals since 2015
Source: FDA 510(k) and PMA databases, 510(k) clearances, and PMA approvals or changes, since 2015; newest shown. Retrieved 13 Nov 2026.
Studies MediLink Therapeutics (Suzhou) Co., Ltd. leads, by the year they started and their phase
Source: ClinicalTrials.gov, Studies with MediLink Therapeutics (Suzhou) Co., Ltd. or a part of it as lead sponsor, by start year (since 2015) and phase. Retrieved 13 Nov 2026.
Markets we cover where free public records show MediLink Therapeutics (Suzhou) Co., Ltd.: trials they lead, US approvals or WHO prequalification. Each opens the market's report, with the record counts and their sources.
The topics of the markets MediLink Therapeutics (Suzhou) Co., Ltd. is in.
Stories on the topics MediLink Therapeutics (Suzhou) Co., Ltd. works in.
Anaemia affects about half a billion women worldwide, and folic acid before pregnancy prevents serious birth…
Read
Collagen powders promise younger skin and easier joints. A 2025 review of 23 trials found the benefits…
Read
About 321,000 people were diagnosed with brain and nervous system tumours in 2022, and about 248,000 died…
ReadSearch all reports for MediLink Therapeutics (Suzhou) Co., Ltd. All companies